{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-022193","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.391623+00:00","generated_at":"2026-06-01T07:10:52.739223+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Oncocyte approves salary increases for CEO, interim CFO, and CSO effective May 20, 2024","bullets":["CEO Joshua Riggs' base salary increased from $360,000 to $400,000.","Interim CFO/Principal Accounting Officer James Liu's salary raised from $200,000 to $207,000.","Chief Science Officer Ekkehard Schütz's salary rose from $351,525 to $378,025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-022193","json":"https://secwatch.observer/filing/0001493152-24-022193.json","markdown":"https://secwatch.observer/filing/0001493152-24-022193.md","text":"https://secwatch.observer/filing/0001493152-24-022193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224022193/0001493152-24-022193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224022193/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:10:52.739223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}